<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Discover Robust 3D Ex Vivo Compound Screening

Ex vivo cancer pharmacology has shown advantages over in vitro and in vivo approaches in preclinical drug discovery and development. With regards to patient-derived xenograft (PDX) use, a 3D ex vivo assay overcomes model limitations such as low throughput in candidate drug screening and high cost and time consuming studies.